March 1, 1991Journal of Hypertension

Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly

View Full Paper

Ask AI

Bookmark

Why the study?

Does active antihypertensive treatment with triamterene/hydrochlorothiazide and methyldopa reduce cardiovascular events and what are its adverse effects in hypertensive patients over 60 years of age?

Population

840 hypertensive patients over the age of 60 years (n=416 active, n=424 placebo)

Comparison

Triamterene 50 mg plus hydrochlorothiazide 25… vs Matching placebo capsules and tablets

Design

RCT, double-blind

Authors

AFAstrid Fletcher AAA Amery WBW. H. Birkenhäger

Discussion

Member takes

Overview

Supports antihypertensive therapy in elderly hypertensives to reduce CV events; confirms net benefit despite renal and metabolic risks.

Structured PICO

Does active antihypertensive treatment with triamterene/hydrochlorothiazide and methyldopa reduce cardiovascular events and what are its adverse effects in hypertensive patients over 60 years of age?

Population

840 hypertensive patients over the age of 60 years (n=416 active, n=424 placebo)

Intervention

Triamterene 50 mg plus hydrochlorothiazide 25 mg (dose could be doubled), with methyldopa (up to 2 g daily) added in 35% of patients when blood pressure remained high

Comparator

Matching placebo capsules and tablets

Outcome

Adverse effects (abnormal biochemical results, investigator reports of diseases, prescriptions of concomitant therapy, self-administered symptom questionnaire) and cardiovascular events (fatal cardiac events, strokes, severe congestive heart failure)hard clinical

Active antihypertensive treatment in elderly patients prevents major cardiovascular events but is associated with increased risks of renal impairment, hypokalemia, and gout.

Cite This Study

Fletcher et al. (1991) studied this question.

synapsesocial.com/papers/6a7d2945a3b6fd5035d5a6d8 https://doi.org/10.1097/00004872-199103000-00005

View Full Paper

Ask AI

Bookmark

March 1, 1991Journal of Hypertension

Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly

View Full Paper

Ask AI

Bookmark

Why the study?

Does active antihypertensive treatment with triamterene/hydrochlorothiazide and methyldopa reduce cardiovascular events and what are its adverse effects in hypertensive patients over 60 years of age?

Population

840 hypertensive patients over the age of 60 years (n=416 active, n=424 placebo)

Comparison

Triamterene 50 mg plus hydrochlorothiazide 25… vs Matching placebo capsules and tablets

Design

RCT, double-blind

Authors

AFAstrid Fletcher AAA Amery WBW. H. Birkenhäger

Discussion

Member takes

Overview

Supports antihypertensive therapy in elderly hypertensives to reduce CV events; confirms net benefit despite renal and metabolic risks.

Structured PICO

Does active antihypertensive treatment with triamterene/hydrochlorothiazide and methyldopa reduce cardiovascular events and what are its adverse effects in hypertensive patients over 60 years of age?

Population

840 hypertensive patients over the age of 60 years (n=416 active, n=424 placebo)

Intervention

Triamterene 50 mg plus hydrochlorothiazide 25 mg (dose could be doubled), with methyldopa (up to 2 g daily) added in 35% of patients when blood pressure remained high

Comparator

Matching placebo capsules and tablets

Outcome

Active antihypertensive treatment in elderly patients prevents major cardiovascular events but is associated with increased risks of renal impairment, hypokalemia, and gout.

Cite This Study

Fletcher et al. (1991) studied this question.

synapsesocial.com/papers/6a7d2945a3b6fd5035d5a6d8 https://doi.org/10.1097/00004872-199103000-00005

View Full Paper

Ask AI

Bookmark